Key clinical point: There is no significant association between use of beta-blockers and improved clinical outcomes in women with breast cancer.
Major finding: Beta-blocker use was not associated with breast cancer recurrence (risk ratio [RR], 0.85; P = .17), breast-cancer-related mortality (RR, 0.83; P = .14), and all-cause mortality (RR, 1.01; P = .91).
Study details: A meta-analysis of 17 observational studies including 75,074 patients with breast cancer.
Disclosures: The study did not receive any funding. The authors declared no conflicts of interest.
Li C et al. Biosci Rep. 2020 May 21. doi: 10.1042/BSR20200721.